# Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

> **NCT05332704** · PHASE1 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ONO-4685
- **DRUG:** Placebo
- **DRUG:** ONO-4685
- **DRUG:** Placebo
- **DRUG:** ONO-4685
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05332704
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-25
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332704, "Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05332704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*